Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma

Cancers (Basel). 2024 Apr 25;16(9):1652. doi: 10.3390/cancers16091652.

Abstract

Rhabdomyosarcoma is a pediatric cancer associated with aggressiveness and a tendency to develop metastases. Fusion-negative rhabdomyosarcoma (FN-RMS) is the most commonly occurring subtype of RMS, where metastatic disease can hinder treatment success and decrease survival rates. RMS-derived exosomes were previously demonstrated to be enriched with miRNAs, including miR-1246, possibly contributing to disease aggressiveness. We aimed to decipher the functional impact of exosomal miR-1246 on recipient cells and its role in promoting aggressiveness. Treatment of normal fibroblasts with FN-RMS-derived exosomes resulted in a significant uptake of miR-1246 paired with an increase in cell proliferation, migration, and invasion. In turn, delivery of miR-1246-mimic lipoplexes promoted fibroblast proliferation, migration, and invasion in a similar manner. Conversely, when silencing miR-1246 in FN-RMS cells, the resulting derived exosomes demonstrated reversed effects on recipient cells' phenotype. Delivery of exosomal miR-1246 targets GSK3β and promotes β-catenin nuclear accumulation, suggesting a deregulation of the Wnt pathway, known to be important in tumor progression. Finally, a pilot clinical study highlighted, for the first time, the presence of high exosomal miR-1246 levels in RMS patients' sera. Altogether, our results demonstrate that exosomal miR-1246 has the potential to alter the tumor microenvironment of FN-RMS cells, suggesting its potential role in promoting oncogenesis.

Keywords: Rhabdomyosarcoma; aggressiveness; exosomes; fusion-negative RMS; miR-1246; paracrine signaling.

Grants and funding

This research was funded by a grant from the Lebanese University, a research grant from PHC-Cedre 2020, and a grant by Ligue Contre le Cancer (Comité du Rhône, France). It was also supported by the LabEX DEVweCAN (ANR-10-LABX-61) of the University Lyon 1 “Investissements d’Avenir” (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR). Use of biospecimens from the COG was supported by the following grants: NCTN Operations Center Grant U10CA180886; NCTN Statistics & Data Center Grant U10CA180899; COG Biospecimen Bank Grant U24CA196173; WWWW Foundation, Inc. (also known as the QuadW Foundation). Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.